Research map: A comparative performance evaluation of the VIDAS cytomegalovirus (CMV) interferon-gamma release assay (IGRA) and T-SPOT CMV for measuring CMV-specific T-cell responses in allogeneic hematopoietic stem cell transplant recipients receiving letermovir prophylaxis

Back to the article

Papers in this map

  1. Pathogenesis of human cytomegalovirus in the immunocompromised host · Paul Griffiths · 2021 · 650 citations · Cited by this paper
  2. Alterations in Serum Interleukin-6 and Interleukin-8 Levels Associated with Mycobacterium tuberculosis Infection in Patients with Type 2 Diabetes Mellitus: A Case Control Study from Mexico · Laura Lourdes · 2026 · Cites this paper
  3. Legionella 5S rRNA PCR melting temperature analysis discriminates high-risk species associated with disease severity · 2026 · Related
  4. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum · Per T Ljungman · 2024 · 187 citations · Cited by this paper
  5. A multiparameter whole blood platform for assessment of anti-CMV immunity in allogeneic stem cell transplantation recipients · Nina Imhof · 2026 · Cites this paper
  6. Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales · 2026 · Related
  7. The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation · Camille N. Kotton · 2025 · 182 citations · Cited by this paper
  8. Post-pandemic surge of Mycoplasma pneumoniae in Ontario, 2024: molecular surveillance and resistance trends relative to 2018–2023 · 2026 · Related
  9. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation · Danniel Zamora · 2021 · 171 citations · Cited by this paper
  10. Photo Quiz: Persistent eyelash debris in a 10-year-old female · 2026 · Related
  11. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study · Roy F. Chemaly · 2020 · 118 citations · Cited by this paper
  12. Performance of the Techcyte AI-based image analysis system for coproparasitological diagnosis in clinical stool specimens: a retrospective evaluation study · 2026 · Related
  13. Comparison of Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV Quantiferon Gamma Interferon-Releasing Assays in Assessing Risk of CMV Infection in Kidney Transplant Recipients · Davide Abate · 2013 · 108 citations · Cited by this paper
  14. Stool antigen-based enzyme immunoassays: performance evaluations and automation · 2026 · Related
  15. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies · Per T Ljungman · 2025 · 84 citations · Cited by this paper
  16. Multicenter evaluation of low inoculum and a colorimetric assay for antifungal susceptibility testing of Aspergillus fumigatus to echinocandins with the EUCAST E.Def 9.4 · 2026 · Related
  17. Utility of the Enzyme-Linked Immunospot Interferon-γ–Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients · Lior Nesher · 2016 · 83 citations · Cited by this paper
  18. Xpert MTB/XDR performance in non-sputum samples for diagnosis of drug-resistant tuberculosis at a North Indian tertiary care center · 2026 · Related
  19. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients · Lynn El Haddad · 2018 · 75 citations · Cited by this paper
  20. Synonymous codon-optimized multiplex qPCR for simultaneous detection of Helicobacter pylori and precise drug resistance profiling in infected individuals · 2026 · Related
  21. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection · Angela Chiereghin · 2018 · 59 citations · Cited by this paper
  22. Masking recurrent contaminants in reference sequences improves specificity of clinical metagenomic sequencing · 2026 · Related
  23. Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+T-Cell Response in Allogeneic Stem Cell Transplant Recipients · María Ángeles Clari · 2012 · 54 citations · Cited by this paper
  24. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment · Mario Fernández‐Ruiz · 2018 · 54 citations · Cited by this paper
  25. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis · Elisa Gabanti · 2022 · 52 citations · Cited by this paper
  26. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients · Smaranda Gliga · 2018 · 44 citations · Cited by this paper
  27. CMV Antigen-Specific CD4 + and CD8 + T Cell IFNγ Expression and Proliferation Responses in Healthy CMV-Seropositive Individuals · Elizabeth Sinclair · 2004 · 38 citations · Cited by this paper
  28. Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use? · Oriol Bestard · 2023 · 37 citations · Cited by this paper
  29. Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients · Smaranda Gliga · 2021 · 29 citations · Cited by this paper
  30. CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients · Laura Donadeu · 2020 · 27 citations · Cited by this paper
  31. Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update · Elisa Ruiz-Arabi · 2024 · 24 citations · Cited by this paper
  32. Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same? · Rutger Callens · 2023 · 22 citations · Cited by this paper
  33. Features of cytomegalovirus DNAemia and virus‐specific T‐cell responses in allogeneic hematopoietic stem‐cell transplant recipients during prophylaxis with letermovir · Estela Giménez · 2023 · 18 citations · Cited by this paper
  34. Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant · Ella Ariza‐Heredia · 2023 · 15 citations · Cited by this paper
  35. Current and Future Strategies for the Prevention and Treatment of Cytomegalovirus Infections in Transplantation · Madeleine R. Heldman · 2024 · 15 citations · Cited by this paper
  36. Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients · Luxiang Wang · 2025 · 14 citations · Cited by this paper
  37. Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients · Federica Zavaglio · 2023 · 13 citations · Cited by this paper
  38. Comparison of intracellular cytokine staining versus an ELISA‐based assay to assess CMV‐specific cell‐mediated immunity in high‐risk kidney transplant recipients · Mario Fernández‐Ruiz · 2023 · 12 citations · Cited by this paper
  39. CMV immune monitoring—Where do we go from here? · Deepali Kumar · 2020 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)